News
No survival benefit from aspirin in COVID-19 patients
Findings of the UK RECOVERY trial show that use of aspirin in the hope of reducing blood clotting in patients hospitalised with COVID-19 does not have any impact on survival.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Findings of the UK RECOVERY trial show that use of aspirin in the hope of reducing blood clotting in patients hospitalised with COVID-19 does not have any impact on survival.